Stivarga

Chemical Nameregorafenib
Dosage FormTablet (oral; 40 mg)
Drug ClassKinase inhibitors
SystemDigestive
CompanyBayer
Approval Year2012

Indication

  • For the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an antiVEGF therapy, and, if RAS wild-type, an anti-EGFR therapy
  • For the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate
  • For the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib
Last updated on 4/21/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Stivarga (regorafenib) Prescribing Information.2012Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ
Document TitleYearSource
Second‑line treatments for advanced hepatocellular carcinoma: a systematic review and bayesian network meta‑analysis. 2022Clinical and Experimental Medicine
Health-related quality of life and side effects in gastrointestinal stromal tumor (GIST) patients treated with tyrosine kinase inhibitors: a systematic review of the literature. 2022Cancers
Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis. 2021Cochrane Database of Systematic Reviews
A systematic review and network meta-analysis of second-line therapy in hepatocellular carcinoma.2020Current Oncology
Systematic review and network meta‑analyses of third‑line treatments for metastatic colorectal cancer.2020Journal of Cancer Research and Clinical Oncology
Systemic therapy and sequencing options in advanced hepatocellular carcinoma: a systematic review and network meta-analysis. 2020JAMA Oncology
Efficacy and safety of regorafenib in combination with chemotherapy as second-line treatment in patients with metastatic colorectal cancer: a network meta-analysis and systematic literature review.2020Advances in Therapy
Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: a meta-analysis of approximately 29,000 cancer patients.2020European Journal of Preventive Cardiology
A systematic review and network meta-analysis of regorafenib and TAS-102 in refractory metastatic colorectal cancer.2019The Oncologist
Comparison of regorafenib, fruquintinib, and TAS-102 in previously treated patients with metastatic colorectal cancer: a systematic review and network meta-analysis of five clinical trials.2019Medical Science Monitor
A meta-analysis of safety and efficacy of regorafenib for refractory metastatic colorectal cancer.2018Medicine
Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review.2018Annals of Oncology
A systematic review and network meta-analysis of post-imatinib therapy in advanced gastrointestinal stromal tumour.2017Current Oncology
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumor after failure with imatinib and sunitinib treatment.2017Medicine
Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: a systematic review. 2017Cancer Treatment Reviews
Anti-angiogenic therapy in patients with advanced gastric and gastroesophageal junction cancer: a systematic review.2017Cancer Research and Treatment
Second- and third-line systemic therapy in patients with advanced esophagogastric cancer: a systematic review of the literature.2016Cancer Metastasis review